LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Elenco Azioni・Cytokinetics Inc

Cytokinetics Inc

Chiusa

SettoreSettore sanitario

78.75 3.73

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

75.97

Massimo

79.03

Metriche Chiave
By Trading Economics
Entrata	-23M -206M
Vendite	1.6M 19M
EPS	-1.67
Margine di Profitto	-1,064.485
Dipendenti	673
EBITDA	112K -180M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+25.17% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2B 10B
Apertura precedente	75.02
Chiusura precedente	78.75

Notizie sul Sentiment di mercato

By Acuity

91%

330 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

32.3 / 40.43 Supporto e resistenza

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 mag 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mag 2026, 22:52 UTC

I principali Market Mover

Osisko Shares Fall on Planned Convertible Notes Offering

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mag 2026, 23:44 UTC

Utili

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mag 2026, 23:35 UTC

Discorsi di Mercato

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mag 2026, 23:30 UTC

Discorsi di Mercato

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 23:17 UTC

Discorsi di Mercato

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mag 2026, 23:15 UTC

Discorsi di Mercato

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mag 2026, 23:14 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mag 2026, 23:02 UTC

Discorsi di Mercato

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

20 mag 2026, 22:57 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mag 2026, 22:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 mag 2026, 22:27 UTC

Discorsi di Mercato

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mag 2026, 22:14 UTC

Discorsi di Mercato

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mag 2026, 22:10 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mag 2026, 22:00 UTC

Utili

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mag 2026, 21:38 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mag 2026, 21:27 UTC

Utili

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mag 2026, 21:20 UTC

Utili

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mag 2026, 21:19 UTC

Utili

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mag 2026, 21:18 UTC

Utili

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mag 2026, 21:17 UTC

Utili

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mag 2026, 21:17 UTC

Utili

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mag 2026, 21:16 UTC

Utili

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

25.17% in crescita

Previsioni per 12 mesi

Media 98.6 USD 25.17%

Alto 140 USD

Basso 67 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 20 che hanno fornito valutazioni azionarie a Cytokinetics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

32.3 / 40.43Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

330 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.